| 8.30 | |
Registration & Coffee
|
| 9.00 | |
Chairman's Opening RemarksNathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa View Bio |
| 9.10 |  |
Taking a 3 Dimensional approach to cell based assaysAnthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin View Bio
- Why are 3D cell culture and assay technologies considered better than conventional 2D
- When and how should these assays be deployed into your research programme
- What currently is available and how it is being used
|
| 9.45 | |
Alvetex 3D cell culture technology and applications for high throughput screening of liver toxicity and cancer assaysStefan Przyborski, Founder and CSO, Reinnervate View Bio
- Conventional 2D cell culture models provide poor proxy for real tissues, where does 3D take us
- Alvetex technology has been developed as a solution for simple and routine 3D cell culture that adds significant value to the culture model
- Alvetexand applications including liver toxicity, cancer cell biology, and physiologically relevant cell based assays
- Demonstrations in application for use in validation and high throughput studies
|
| 10.25 | |
Morning Coffee
|
| 10.55 | |
Tecan’s Infinite® 200 PRO – the reader with integrated cell incubatorChristian Oberdanner, Marketing Application Specialist, Tecan Austria GmbH View Bio
- How often do you transfer your microplate between the incubator and plate reader
- Simultaneous, independent adjustment of CO2 and O2
- Consistent physiological conditions for predictable culture growth
- True walkway operation reducing labor time & improving productivity
- No gaps in data during overnight or long running experiments
|
| 11.35 | |
Comparison of different 3D cell culture models for their application in high throughput screeningRosalia Arrebola, Scientist, Lead Identification Technologies & Kinases, Sanofi Aventis View Bio
- Pragmatic approaches for high throughput screening
- 2D verses 3D
- 3D kinase cell based assays
|
| 12.10 | |
Networking Lunch
|
| 13.10 | |
3D tumour spheroids for drug discovery in oncologyCarsten Wenzel, Scientist, Bayer View Bio
- Advances in high content screening on 3D tumour spheroids
- 3D assay development
- Tumour micro environment
|
| 13.45 | |
A Novel, Rapid and Reproducible Method for Creating 3D Cell Cultures to Study Complex Cell BehaviorGrant Cameron, Development Director, TAP Biosystems View Bio
- Ceating complex 3D cell cultures in a simple, consistent & reproducible format
- Using physiologically relevant collagen concentrations to create the most natural environment for cells
- Enabling scientists to take complete control of their experiments by using their own cell type(s) and selecting seeding density
|
| 14.25 | |
Molecular Characterisation of the tumor stroma crosstalk using a novel 3D co-culture iv vitro modelAlbin Rudisch, Scientist, Boehringer Ingelheim Pharma Informacios Es Szerviz Iroda View Bio
- Identifying molecular mechanisms in the cross talk between small cell lung cancer (NSCLC) and corresponding CAFs
- Novel and complex 3D organtypic (spheroid) in vitro cell culture model system has been established
- Advantages in vivo situation reflecting the complexity and dynamics of human tumors more faithfully than 2D monotypic monolayer cultures
|
| 15.00 | |
Afternoon Tea
|
| 15.35 | |
Roles of ion channels in cell-based drug discovery — New strategies and techniques enabling attrition reduction strategies David Standing, Senior Scientist, GlaxoSmithKline View Bio
- Role of ion channels in attrition reduction strategy
- Screening and triage strategies for characterizing on and off target ion channel activity
- Enhanced capabilities of new electrophysiology platforms such as Barracuda to deliver reliable, robust, predicative and cost effective decision making data
|
| 16.10 | |
Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogatesPaul Groot-Kormelink , Investigator III, Novartis Pharmaceuticals View Bio
- High throughput gene expression enabling re-evaluation of surrogate cell types for cellular models
- Introductions to dynamically regulated families of integral membrane proteins
- Similarities and differences in ion channel and g-protein couples receptors between alveolar macrophages and their surrogates
|
| 16.50 | |
Using GPCR signalling assays to study chemokine biology and develop novel anti-inflammatory drugsAsif Iqbal, Post-Doc Research Scientist, Oxford University View Bio
- CC chemokine signalling followed by electrical cell-substrate impendence for sensing ECIS and beta arrestin recruitment
- Label free assays for galphai couples GPCRs and screening for novel cannaboids active at the CB2 receptor
- Development of real time chemotaxis
|
| 17.30 | |
Chairman’s Closing Remarks and Close of Day OneNathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa View Bio |